YOLFTbeta
Suzhou Zelgen Biopharmaceuticals Co Ltd

Suzhou Zelgen Biopharmaceuticals Co Ltd

688266 · SHG · Healthcare / Biotechnology

85.05CNY-2.56 (-2.92%)

Price History

Full chart

Market Stats

Previous Close87.61
Open86.81
Day Range84.37 – 88.68
52-Week Range75.10 – 160.00
Volume4.01M
Market Cap29.12B
P/E (TTM)52.88
Forward P/E0.00
EPS2.08
Dividend Yield0.00%
Beta-0.12
50-Day Avg118.54
200-Day Avg103.78

About

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for hemostasis. It also develops gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, and myelofibrosis; recombinant human thyroid-stimulating hormone for injection; and ZG006 for injection, indications for small cell lung cancer, neuroendocrine carcinoma, and other advanced tumors. In addition, it develops ZG005 for injection, which is in phase I/II clinical trial for cervical cancer, liver cancer, neuroendocrine carcinoma and other advanced tumors; and ZGGS18, ZGGS15, ZGGS34, ZG016, ZG2273, ZG2001film, and ZG0895 hydrochloric acid for injection indications for advance tumors. The company's products are used in multiple therapeutic areas, such as tumors and hematological diseases, bleeding and trauma, and immune inflammatory diseases. Suzhou Zelgen Biopharmaceuticals Co., Ltd. was founded in 2009 and is based in Kunshan, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Zelin Sheng
  • Employees1.05K
  • HeadquartersNo. 209, Chenfeng Road, Kunshan, China, 215300, China
  • Websitehttps://zelgen.com

Leadership

  • Mr. Zelin ShengChairman of the Board & GM · b. 1960
  • Mr. Gang HuangCFO & Deputy GM · b. 1971
  • Ms. Zeqi ShengChief Scientific Officer · b. 1964
  • Ms. Huiping LuExecutive VP & Director · b. 1967
  • Mr. Jisheng WuDeputy General Manager · b. 1965
  • Mr. Binhua LyuDeputy GM, EVP of Chemistry & Director · b. 1979
  • Ms. Qingping GaoDeputy GM & Board Secretary · b. 1977
  • Shice ShaoHead of Accounting Department

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue200.33K01.31M027.66M190.36M302.31M386.44M532.95M812.73M
Growth (%)--100.00%--100.00%-+588.19%+58.81%+27.83%+37.91%+52.50%
Cost of Revenue195.81K237.77K1.23M175.80K566.09K7.10M27.53M31.42M37.72M77.63M
Gross Profit4.53K-237.77K82.58K-175.80K27.09M183.26M274.78M355.02M495.23M812.73M
Gross Margin2.26%-6.30%-97.95%96.27%90.89%91.87%92.92%100.00%
Operating Expense133.64M146.23M442.73M439.61M331.92M642.31M760.33M652.80M650.27M978.50M
Operating Income-133.63M-146.47M-442.65M-439.79M-304.83M-459.04M-485.56M-297.78M-155.04M-165.76M
Operating Margin-66705.10%--33760.07%--1102.02%-241.14%-160.62%-77.06%-29.09%-20.40%
EBITDA-122.54M-141.51M-434.29M-405.63M-268.61M-416.69M-420.51M-232.72M-83.03M-123.48M
EBITDA Margin-61165.63%--33122.96%--971.10%-218.89%-139.10%-60.22%-15.58%-15.19%
Net Income-128.27M-146.47M-440.09M-461.88M-319.23M-451.00M-457.33M-278.58M-137.83M-160.70M
Net Income Margin-64027.01%--33564.91%--1154.08%-236.92%-151.28%-72.09%-25.86%-19.77%
R&D61.08M158.82M142.81M183.84M314.20M509.39M497.73M496.33M388.00M429.91M
R&D as % of Total Revenue30487.79%-10891.53%-1135.89%267.59%164.64%128.44%72.80%52.90%
Interest Expense0030.61K1.16M1.50M6.20M14.94M24.45M29.10M24.20M
Interest Expense % of Total Revenue0.00%-2.33%-5.42%3.26%4.94%6.33%5.46%2.98%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets137.20M147.63M454.88M320.27M1.97B1.75B1.67B2.89B3.00B2.97B
Total Liabilities27.76M74.61M173.24M246.52M278.69M492.88M880.82M1.24B1.75B1.89B
Total Equity109.44M73.02M226.31M3.43M1.62B1.20B759.12M1.63B1.25B1.08B
Cash17.03M9.88M128.93M66.92M1.15B1.14B797.05M2.11B2.15B2.03B
Total Debt--4.53M60.00M47.70M223.57M547.80M824.62M1.02B-
Net Debt-17.03M-9.88M-124.41M-6.92M-1.10B-913.06M-249.25M-1.22B-1.13B-

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-56.72M-108.25M-112.44M-180.43M-343.86M-454.62M-370.34M-220.31M38.20M-28.78M
Investing Cash Flow-57.43M-8.83M-53.11M63.33M-499.25M326.66M-264.06M52.40M-1.85B-
Financing Cash Flow124.79M110.06M285.37M54.32M1.90B93.99M282.79M1.51B-51.32M-
Capital Expenditure24.32M11.66M11.08M15.11M57.68M70.74M88.62M62.60M95.69M181.47M
Free Cash Flow-81.04M-119.91M-123.52M-195.53M-401.54M-525.36M-458.97M-295.35M-57.49M-210.25M
Dividends Paid-1.11M1.11M1.16M1.11M4.14M11.22M21.17M24.56M26.09M
FCF to OCF142.88%110.77%109.86%108.37%116.77%115.56%123.93%134.06%-150.47%730.49%
Dividend Paid to FCF--0.93%-0.90%-0.59%-0.28%-0.79%-2.44%-7.17%-42.73%-12.41%

Earnings

Report DateJan 6, 2020Apr 28, 2020Aug 16, 2020Oct 29, 2020Feb 25, 2021Apr 29, 2021Aug 25, 2021Oct 26, 2021Feb 23, 2022Apr 26, 2022Aug 18, 2022Oct 27, 2022Dec 31, 2022Apr 21, 2023
EPS Estimate0.00-------------
EPS Actual-0.32-0.28-0.29-0.23-0.38-0.33-0.40-0.48-0.66-0.50-0.53-0.49-0.39-0.39
Surprise--------------
Timing-Pre-marketAfter-hoursPre-marketPre-market-After-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap29.12B
Enterprise Value29.06B
Trailing P/E52.88
Forward P/E0.00
Price / Sales17.75
Price / Book17.86
EPS2.08
Book Value6.50
Revenue (TTM)1.64B
Gross Profit (TTM)1.53B
EBITDA496.32M
Profit Margin33.52%
Operating Margin-6.53%
Return on Equity38.00%
Return on Assets8.81%
Shares Outstanding264.71M
Shares Float167.26M
Beta-0.12
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%